ATAI Life Sciences NV (ATAI) Actualités

atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01...

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...

atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities